The FDA is out there protecting you.... that is why you will find

[HysteryDiagnosis]

information such as this on the front pages of national newspapers daily.

What you might not know, is that the FDA has authorized a qualified health claim, stating that consumption of EPA and DHA Omega-3 fatty acids may reduce the risk of coronary heart disease (CHD). Moreover, there’s mounting evidence Omega-3s also can help manage triglyceride levels, high blood pressure, atherosclerosis, arrhythmia, multiple sclerosis, and brain development. A recent meta-analysis of 97 clinical studies even demonstrated Omega-3s have a beneficial effect on mortality.

Specifically, the American Heart Association recommends anyone with documented coronary heart disease consume about 1 g of EPA+DHA per day, and that patients who need to lower triglycerides take 2 to 4 grams of EPA+DHA per day provided as capsules. However, the AHA concedes that coronary artery disease patients may not be able to obtain an ample amount of Omega-3s by diet alone.

[Dr.Phool]

1. Which brings me back to an article I read last week

Nutty Hemp seems to be a rich source of balanced Omega 3's

Maybe I'll try some of this to help with my high blood pressure.

http://www.msnbc.msn.com/id/16637630/

[HysteryDiagnosis]

2. I find coenzyme Q10 to be of value in this arena

1: J Cardiovasc Nurs. 2006 Jan-Feb;21(1):9-16.Click here to read Links
Supplemental conditionally essential nutrients in cardiovascular disease therapy.

* Kendler BS.

Dept. of Biology, CMSV Campus, Manhattan College, Riverdale, NY 10471, USA. [e-mail]

Conditionally essential nutrients (CENs) are organic compounds that are ordinarily produced by the body in amounts sufficient to meet its physiological requirements. However, in disorders, such as cardiovascular disease (CVD), and in other physiologically stressful conditions, their biosynthesis may be inadequate. Under these circumstances, CENs become essential nutrients, comparable to vitamins. The CENs of primary importance in CVD, based on the quantity and quality of human clinical studies, are l-arginine, l-carnitine, propionyl-l-carnitine, and coenzyme Q10. Controlled studies of these CENs are reviewed in depth. Taurine is a CEN of secondary importance caused by a limited human database. Other putative CENs include alpha-lipoic acid, betaine, chondroitin sulfate, glutamine, and d-ribose, each of which is mentioned in passing. Collectively, CENs have demonstrated favorable clinical effects in CVDs, including chronic heart failure, myocardial infarction, angina pectoris, and in CVD risk factors, such as hypertension, hyperlipidemia, and lipoprotein(a). Limited research has pointed to possible benefits in CVD therapy accruing from supplementation with several CENs in combination. Additional controlled clinical studies of CENs in CVD are urgently needed. In view of the efficacy and safety of appropriate supplementation with CENs, it is strongly suggested that healthcare professionals become knowledgeable of these potentially important additions to the CVD therapeutic armamentarium.

PMID: 16407731




1: Vopr Pitan. 2006;75(2):37-9. Links

* Eshginia S,
* Gapparov MM.

It was investigated the influence of dietary therapy by adding phospholipids (5 gr/daily lecithin) and antioxidant agents (90 mg/daily coenzyme Q10) on clinical and biochemical parameters at patients with hypertension I and II stages. At the end of the 4-week period, decreased systolic and diastolic blood pressure, level of the total cholesterol, lipoprotein low density (LDL) and apolipoprotein A1 in their plasma.

PMID: 16729759